Facultad de Medicina
Facultad
Luis Miguel
Blanco Colio
Publicaciones en las que colabora con Luis Miguel Blanco Colio (21)
2023
-
Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?
Frontiers in Cardiovascular Medicine, Vol. 10
2022
-
Annexins and cardiovascular diseases: Beyond membrane trafficking and repair
Frontiers in Cell and Developmental Biology, Vol. 10
-
Galectin-1 prevents pathological vascular remodeling in atherosclerosis and abdominal aortic aneurysm
Science Advances, Vol. 8, Núm. 11
2021
-
Anexinas: implicación en la homeostasis del colesterol, la respuesta inflamatoria y la aterosclerosis
Clínica e investigación en arteriosclerosis, Vol. 33, Núm. 4, pp. 206-216
-
Cellular crosstalk between endothelial and smooth muscle cells in vascular wall remodeling
International Journal of Molecular Sciences, Vol. 22, Núm. 14
-
Mcp-1 predicts recurrent cardiovascular events in patients with persistent inflammation
Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-13
2020
-
CD163 deficiency increases foam cell formation and plaque progression in atherosclerotic mice
FASEB Journal, Vol. 34, Núm. 11, pp. 14960-14976
-
The TNF-like weak inducer of the apoptosis/fibroblast growth factor–inducible molecule 14 axis mediates histamine and platelet-activating factor–induced subcutaneous vascular leakage and anaphylactic shock
Journal of Allergy and Clinical Immunology, Vol. 145, Núm. 2, pp. 583-596.e6
-
Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges
Cells, Vol. 9, Núm. 2
2019
-
A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis
EBioMedicine, Vol. 46, pp. 274-289
-
Fisiopatología del aneurisma de aorta abdominal: biomarcadores y nuevas dianas terapéuticas
Clínica e investigación en arteriosclerosis, Vol. 31, Núm. 4, pp. 166-177
2018
-
Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease
Atherosclerosis, Vol. 270, pp. 13-20
2017
-
Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease
Atherosclerosis, Vol. 260, pp. 130-137
-
TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice
Scientific Reports, Vol. 7
2014
-
Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis
Journal of the American Heart Association, Vol. 3, Núm. 4
2008
-
TWEAK, el facilitador del daño renal agudo
Nefrologia
-
TWEAKing renal injury
Frontiers in Bioscience, Vol. 13, Núm. 2, pp. 580-589
2007
-
HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: Role of RhoA/ROCK and MAPK pathways
Hypertension, Vol. 50, Núm. 2, pp. 377-383
2005
-
The Rho-kinase pathway regulates angiotensin II-induced renal damage
Kidney International
2004
-
Los inhibidores de la HMG-CoA reductasa regulan la síntesis del factor de crecimiento de tejido conectivo (CTGF) inducido por la angiotensina II. ¿Un efecto adicional vasoprotector?
Investigacion Cardiovascular, Vol. 7, Núm. 1, pp. 60-80